MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：15

作者：

Patel, V. ^{[1
]}

Mansi, J. ^{[2
]}

Ghosh, S. ^{[2
]}

Kwok, J. ^{[1
]}

Burke, M. ^{[3
]}

Reilly, D. ^{[3
]}

Nizarali, N. ^{[3
]}

Sproat, C. ^{[1
]}

Chia, K. ^{[2
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Oral Surg, Fl 23,Tower Wing, London SE1 9RT, England

[2] Guys & St Thomas NHS Fdn Trust, Dept Oncol, Fl 23,Tower Wing, London SE1 9RT, England

[3] Guys & St Thomas NHS Fdn Trust, Sedat & Special Care, Fl 23,Tower Wing, London SE1 9RT, England

来源：

BRITISH DENTAL JOURNAL | 2018年 / 224卷 / 02期

关键词：

ZOLEDRONIC ACID; PREVENTIVE MEASURES; OSTEONECROSIS; JAW; IMPLEMENTATION; MANAGEMENT; REDUCE;

D O I：

10.1038/sj.bdj.2017.1039

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.

引用

页码：74 / 79

页数：6

共 50 条

[1] MRONJ risk of adjuvant bisphosphonates in early stage breast cancer
V. Patel
J. Mansi
S. Ghosh
J. Kwok
M. Burke
D. Reilly
N. Nizarali
C. Sproat
K. Chia
British Dental Journal, 2018, 224 : 74 - 79
[2] Adjuvant bisphosphonates for early-stage breast cancer
Brufsky, Adam
LANCET ONCOLOGY, 2011, 12 (07): : 610 - 611
[3] Bisphosphonates in the adjuvant treatment of early breast cancer
Gnant, M.
BREAST CANCER RESEARCH, 2009, 11 : S7 - S7
[4] Bisphosphonates in the adjuvant treatment of early breast cancer
M Gnant
Breast Cancer Research, 11
[5] Adjuvant therapy for early stage breast cancer
Sledge, GW
SEMINARS IN ONCOLOGY, 1996, 23 (01) : 51 - 54
[6] Adjuvant Bisphosphonates and Breast Cancer Survival
Strobl, Stephanie
Korkmaz, Belgin
Devyatko, Yelena
Schuetz, Michael
Exner, Ruth
Dubsky, Peter C.
Jakesz, Raimund
Gnant, Michael
ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 1 - 10
[7] Bisphosphonates as adjuvant therapy for breast cancer
Burkinshaw, Roger
Coleman, Robert
WOMENS HEALTH, 2006, 2 (01) : 115 - 126
[8] Bisphosphonates as adjuvant therapy for breast cancer
Gnant M.
Dubsky P.
Fitzal F.
Bachleitner-Hofmann T.
Exner R.
Blaha P.
Jakesz R.
Schippinger W.
Greil R.
Current Breast Cancer Reports, 2009, 1 (1) : 54 - 63
[9] Bisphosphonates in the Adjuvant Treatment of Breast Cancer
Winter, M. C.
Coleman, R. E.
CLINICAL ONCOLOGY, 2013, 25 (02) : 135 - 145
[10] Bisphosphonates in Adjuvant Therapy of Breast Cancer
Deuber, Heinz Juergen
Theiss, Friedrich
MEDIZINISCHE KLINIK, 2010, 105 (09) : 635 - 646

← 1 2 3 4 5 →